What is the recommended paracetamol dosing regimen for closure of patent ductus arteriosus in preterm infants?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 27, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Paracetamol Dosing for PDA Closure in Preterm Infants

For preterm infants with hemodynamically significant patent ductus arteriosus, intravenous paracetamol should be administered at 15 mg/kg every 6 hours for 3 days, which achieves ductal closure in approximately 78-90% of cases. 1, 2, 3

Standard Dosing Regimen

The established protocol consists of:

  • Initial and maintenance dose: 15 mg/kg intravenously every 6 hours 2, 4, 3
  • Duration: 3 days (total of 12 doses) 2, 5
  • Route: Intravenous administration is preferred in critically ill preterm neonates 2, 3

This dosing achieves therapeutic serum concentrations in 97-98% of patients at steady state, though extreme preterm neonates may be less likely to reach therapeutic levels after the first dose. 3

Alternative Lower-Dose Regimen

A reduced-dose alternative of 10 mg/kg every 8 hours can be considered if hepatotoxicity concerns arise, with an 83% closure rate. 6 This lower dose was developed after one patient experienced significant transaminase elevation with the standard regimen, though this approach provides less frequent dosing and may have slightly lower efficacy. 6

Clinical Context and Indications

Paracetamol should be used when:

  • Contraindications exist to NSAIDs (ibuprofen/indomethacin) 2, 4, 5
  • Previous NSAID therapy has failed 4, 5
  • Risk factors for NSAID complications are present (renal dysfunction, active bleeding, thrombocytopenia) 1, 2

The diagnosis of hemodynamically significant PDA must be confirmed by echocardiography showing ductal diameter ≥1.4 mm/kg, LA:Ao ratio >1.4, unrestrictive pulsatile flow, or reversed diastolic flow in the descending aorta. 2

Monitoring Requirements

Serial echocardiograms should be performed daily during treatment, with repeat imaging 48 hours after completion to confirm closure. 2, 6, 5 Monitor for:

  • Liver function tests (ALT/AST) to detect hepatotoxicity 6, 3
  • Renal function (creatinine, urine output) to identify acute kidney injury 3
  • Clinical signs of bleeding or perfusion changes 1

Approximately 10-18% of patients may develop elevated transaminases, though severe hepatotoxicity is uncommon with the standard regimen. 6, 3

Efficacy and Safety Profile

Paracetamol demonstrates:

  • Closure rates: 78-100% across studies, with most achieving closure within 48 hours 2, 4, 3, 5
  • Lower adverse event profile compared to NSAIDs: no gastrointestinal perforation, minimal renal toxicity, and no bleeding complications 2, 4, 5
  • Effectiveness across gestational ages: 23-33 weeks and birth weights 415-1650g 2, 3, 5

Important Caveats

If ductal closure is not achieved after the first 3-day course, consider a second course of paracetamol or proceed to surgical ligation rather than continuing indefinitely. 7 Very low birth weight infants require particularly careful fluid management during treatment, as rapid volume administration can worsen left-to-right shunting and cause pulmonary edema. 8, 7

The standard ibuprofen regimen (10 mg/kg initial dose, then 5 mg/kg at 24-hour intervals) remains the guideline-recommended first-line pharmacologic therapy, but paracetamol represents a valuable alternative when NSAIDs cannot be used. 9, 1

References

Guideline

Ibuprofen Dosing for Patent Ductus Arteriosus (PDA) Treatment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Ductal closure with intravenous paracetamol: a new approach to patent ductus arteriosus treatment.

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2016

Guideline

Patent Ductus Arteriosus Management in Neonates

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Patent Ductus Arteriosus Management in Children

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is the recommended treatment for pain management or fever reduction in a patient with patent ductus arteriosus (PDA) using paracetamol (acetaminophen)?
What is the recommended dosing for intravenous (IV) acetaminophen?
Is the use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) such as indomethacin or ibuprofen recommended for promoting ductal closure in cases of patent ductus arteriosus (PDA) diagnosed in utero?
What is the treatment protocol for Patent Ductus Arteriosus (PDA) in preterm infants using Tylenol (acetaminophen)?
What medication is indicated for a 2-day-old infant with a suspected patent ductus arteriosus (PDA) presenting with a rough, machinery-like murmur best heard at the left second intercostal space?
When should urate‑lowering therapy be started in a patient with documented hyperuricemia (>6 mg/dL) and gout who is currently not in an acute flare?
What is the appropriate approach to analyzing pleural fluid, including how to differentiate transudate from exudate and subsequent management?
What is the appropriate evaluation and management for a fetus with microcephaly identified on routine obstetric ultrasound (head circumference below the 3rd percentile)?
How should I evaluate and manage anemia in an elderly frail patient with diabetes, heart failure, and severe acute kidney injury (serum creatinine 8 mg/dL)?
In a middle‑aged adult from a high tuberculosis‑prevalence region who presents with a sub‑acute, lymphocyte‑predominant pleural effusion, weight loss and low‑grade fever, what is the role of pleural fluid adenosine deaminase (ADA) measurement in diagnosing tuberculous pleural effusion?
Does sertraline (Zoloft) increase appetite?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.